vasculatur
investig
patient
pulmonari
hypertens
clinic
trial
conduct
univers
toronto
one
recent
complet
zhejiang
univers
china
circul
epc
may
also
play
role
acut
lung
injuri
fibrot
lung
diseas
furthermor
increas
evid
suggest
circul
fibrocyt
contribut
pathophysiolog
fibrot
lung
diseas
thu
may
potenti
therapeut
target
addit
novel
area
investig
develop
includ
increas
explor
threedimension
cultur
system
bioengin
approach
gener
function
lung
tissu
ex
vivo
vivo
mesenchym
stem
cell
msc
found
exert
profound
suppress
effect
immun
cell
pathway
demonstr
safeti
efficaci
phase
trial
immunemedi
diseas
graftversushost
diseas
gvhd
crohn
diseas
recent
public
sever
abstract
present
workshop
demonstr
msc
suppress
lung
injuri
inflamm
sever
mous
model
inflammatori
immunemedi
lung
diseas
area
predict
intens
investig
next
sever
year
progress
continu
made
investig
local
endogen
stem
progenitor
cell
resid
lung
understand
ident
lineag
expans
properti
previous
identifi
endogen
progenitor
popul
includ
variant
clara
cell
bronchoalveolar
stem
cell
basc
side
popul
cell
suggest
increasingli
complex
network
cellular
repair
injuri
recent
embryon
origin
clara
cell
secretori
protein
ccsp
cell
identifi
neonat
mous
lung
postul
play
progenitor
role
adult
lung
howev
studi
endogen
lung
stem
progenitor
cell
complic
role
specif
microenvironment
nich
cell
resid
alter
nich
experiment
protocol
remov
cell
nich
chang
identifi
characterist
biolog
activ
one
challeng
face
field
devis
lineag
trace
studi
mechan
defin
character
explor
potenti
therapeut
andor
patholog
properti
endogen
lung
progenitor
cell
notabl
exist
lung
cancer
stem
cell
area
increas
focu
high
interest
remain
poorli
understood
anoth
challeng
studi
endogen
progenitor
cell
use
mous
model
correl
inform
human
lung
remain
poorli
defin
compar
studi
exogen
cell
lung
repair
use
mous
model
rel
limit
data
patient
model
continu
issu
confus
terminolog
precis
definit
character
specif
cell
popul
notabl
msc
epc
agre
upon
term
stem
cell
progenitor
cell
still
use
vari
degre
clariti
precis
differ
investig
recent
public
continu
complic
comparison
differ
investig
approach
glossari
relev
work
definit
applic
lung
depict
tabl
glossari
necessarili
reflect
overal
consensu
definit
term
undergo
continu
revis
overal
understand
cell
type
mechan
involv
lung
repair
continu
elucid
nonetheless
use
framework
first
session
overview
field
dian
kraus
yale
univers
respect
present
wellington
cardoso
boston
univers
barri
stripp
duke
univers
ivan
bertoncello
australian
stem
cell
center
dougla
ball
john
hopkin
univers
school
medicin
review
current
state
knowledg
endogen
stem
cell
popul
potenti
initi
augment
repair
includ
lesson
learn
lung
develop
role
local
microenvironment
nich
consider
lung
cancer
progenitor
cell
key
point
made
session
stem
cell
oper
defin
sole
intrins
development
potenti
interact
permiss
restrict
microenviron
resid
furthermor
stem
cell
nich
dynam
tempor
nich
capac
modifi
stem
cell
behaviorreadout
differ
context
moreov
stem
cellassoci
marker
uniqu
express
stem
cell
unreli
predictor
stem
cell
potenti
isol
cell
requir
valid
function
assay
lineagetrac
studi
particularli
interrog
isol
cell
histomorphometr
spatial
posit
cue
lost
also
includ
session
present
rick
wetsel
univers
texa
demonstr
cell
phenotyp
characterist
type
alveolar
epitheli
cell
could
deriv
vitro
one
approv
human
embryon
stem
es
cell
line
without
requir
embryoid
bodi
intermedi
although
studi
human
es
cell
restrict
unit
state
limit
inform
exist
work
countri
use
human
es
cell
lung
repair
regener
second
third
session
highlight
advanc
cell
therapi
approach
lung
diseas
also
present
data
clinic
trial
cell
therapi
diseas
new
develop
area
bioengin
approach
cell
therapi
lung
diseas
explor
second
session
present
denni
discher
univers
pennsylvania
mingyao
liu
univers
toronto
explor
effect
physic
environ
threedimension
matric
stem
cell
lung
regener
dario
fauza
boston
children
hospit
demonstr
amniot
fluidderiv
msc
could
use
tracheal
repair
bethani
moor
univers
michigan
kurt
stenmark
univers
colorado
health
scienc
center
review
current
understand
role
fibrocyt
fibrot
lung
diseas
epc
pulmonari
vascular
fibrot
lung
diseas
respect
final
johnni
huard
univers
pittsburgh
present
updat
stem
cell
trial
muscl
diseas
immunomodulatori
effect
stem
cell
explor
third
session
result
phase
clinic
trial
msc
crohn
diseas
present
jane
onken
duke
univers
school
medicin
demonstr
safeti
efficaci
otherwis
treatmentresist
patient
follow
explor
msc
effect
inflammatori
immunemedi
lung
diseas
donald
phinney
tulan
univers
daniel
weiss
univers
vermont
ellen
burnham
univers
colorado
health
scienc
center
duncan
stewart
univers
toronto
present
updat
epc
initi
result
epc
trial
pulmonari
hypertens
conduct
univers
toronto
keith
march
indiana
univers
present
updat
cardiac
trial
donald
fink
us
food
drug
administr
fda
present
perspect
fda
extens
discuss
immunomodul
bioengin
approach
use
msc
stem
cell
popul
identifi
area
high
prioriti
expand
studi
final
session
alan
michelson
nation
institut
health
nih
discuss
systemsbas
strategi
cell
therapi
mike
rosenzweig
john
walsh
respect
presid
pulmonari
fibrosi
foundat
present
perspect
stem
cell
research
view
nonprofit
respiratori
diseas
foundat
confer
conclud
vigor
discuss
futur
research
fund
prioriti
led
darwin
prockop
tulan
univers
confer
discuss
spirit
proceed
clinic
investig
addit
trial
occur
univers
toronto
agre
strong
emphasi
must
continu
place
anim
model
human
lung
diseas
focu
studi
incorpor
relev
function
outcom
measur
nonetheless
safeti
efficaci
result
obtain
msc
crohn
diseas
inflammatori
immunemedi
diseas
suggest
potenti
role
inflammatori
immunemedi
lung
diseas
even
absenc
comprehens
understand
mechan
msc
act
grow
consensu
meet
move
toward
earli
studi
human
determin
safeti
dose
paramet
design
care
control
clinic
trial
offer
patient
benefit
rel
littl
risk
acknowledg
particip
role
endogen
lung
progenitor
cell
cell
therapi
approach
lung
diseas
remain
time
excit
area
studi
nonetheless
mani
area
understand
process
mechan
remain
poorli
understood
recommend
area
continu
futur
investig
present
tabl
extens
detail
session
present
confer
program
execut
summari
speaker
abstract
poster
session
includ
onlin
supplement
comprehens
summari
relev
publish
literatur
sinc
workshop
januari
present
see
report
workshop
comprehens
review
literatur
point
reader
also
refer
number
review
topic
appear
approxim
past
year
structur
engraft
number
public
approxim
past
year
suggest
varieti
bone
marrowderiv
cell
includ
hematopoiet
stem
cell
msc
multipot
adult
progenitor
cell
popul
could
structur
engraft
matur
differenti
airway
alveolar
epitheli
cell
literatur
predominantli
base
studi
mice
use
techniqu
evalu
histolog
demonstr
donorderiv
marrow
cell
recipi
lung
system
administr
male
marrow
cell
femal
recipi
usual
alway
myeloabl
recipi
mous
bone
marrow
review
refer
prior
lung
injuri
usual
requir
observ
engraft
although
lung
injuri
alway
result
increas
appar
engraft
furthermor
myeloabl
regimen
use
usual
total
bodi
irradi
also
believ
contribut
lung
injuri
requir
evid
engraft
smaller
bodi
literatur
clinic
bone
marrow
lung
transplant
also
appear
demonstr
vari
degre
appar
chimer
lung
transplant
recipi
review
refer
howev
recent
report
call
question
whether
epitheli
engraft
fact
occur
sever
technic
issu
contribut
misinterpret
result
initi
report
includ
inadequ
microscop
techniqu
donorderiv
cell
superimpos
resid
airway
alveolar
epitheli
cell
effect
discrimin
exquisit
care
sophist
microscop
approach
includ
confoc
deconvolut
techniqu
must
use
effect
demonstr
potenti
engraft
furthermor
varieti
leukocyt
notabl
airway
alveolar
macrophag
resid
lung
mani
earli
report
use
antibodi
direct
leukocyt
marker
exclud
possibl
cell
donor
origin
detect
airway
alveolar
epithelium
donorderiv
leukocyt
rather
epitheli
cell
tool
use
green
fluoresc
protein
gfp
marker
donorderiv
marrow
cell
obtain
transgen
gfp
mice
recipi
mous
lung
subject
error
presenc
autofluoresc
cell
nonetheless
recent
report
suggest
engraft
donorderiv
airway
andor
alveolar
epithelium
occur
perturb
airway
alveolar
epithelium
lung
injuri
model
observ
msc
bone
marrow
cord
blood
origin
side
popul
cell
plastic
adher
marrow
stromal
cell
full
marrow
transplant
myeloabl
regimen
figur
studi
tend
use
sophist
microscop
analyt
techniqu
nonetheless
epitheli
engraft
gener
rare
except
condit
discuss
parallel
recent
studi
also
continu
demonstr
rare
appar
engraft
pulmonari
interstitium
vasculatur
total
marrow
transplant
varieti
injuri
model
report
suggest
engraft
lung
tissu
circul
donorderiv
cell
occur
certain
condit
usual
previou
perturb
induct
lung
injuri
howev
mani
variabl
still
left
explor
may
increas
epitheli
interstiti
pulmonari
vascular
engraft
circul
donorderiv
cell
wide
rang
lung
injuri
model
use
publish
studi
interestingli
sever
recent
report
suggest
chronic
progress
lung
injuri
may
result
substanti
engraft
type
alveolar
epitheli
cell
interstiti
pulmonari
vascular
cell
donorderiv
cell
mous
rat
model
howev
chronic
lung
injuri
model
result
substanti
engraft
effect
age
either
donor
cell
recipi
also
less
well
explor
although
one
report
demonstr
transplant
whole
marrow
mous
pup
use
varieti
condit
regimen
increas
number
bone
marrowderiv
cell
observ
follow
total
marrow
administr
adult
mice
rout
administr
donorderiv
cell
also
less
well
character
studi
investig
engraft
system
administr
donor
cell
direct
intratrach
administr
msc
also
result
much
appar
epitheli
engraft
nonetheless
area
remain
underexplor
type
marrowderiv
cord
bloodderiv
fulli
differenti
nonpulmonari
cell
might
engraft
lung
epithelium
interstitium
pulmonari
vasculatur
remain
fulli
explor
addit
exist
studi
hemapoiet
stem
cell
hsc
msc
bone
marrow
cord
blood
origin
epc
fibrocyt
possibl
remain
may
cell
popul
could
recruit
lung
local
lung
system
rout
administr
popul
circul
bone
marrowderiv
cytokeratin
cell
describ
particip
reepitheliaz
denud
tracheal
xenograft
popul
cord
blood
cell
term
multiplineag
progenitor
cell
isol
human
cord
blood
induc
vitro
express
prosurfact
c
thu
suggest
deriv
type
alveolar
epitheli
cell
howev
cell
yet
extens
character
describ
result
lung
engraft
vivo
sourc
stem
progenitor
cell
adipos
tissu
also
yet
extens
character
abil
engraft
lung
tissu
howev
abil
structur
engraft
adult
lung
may
sole
properti
stem
progenitor
cell
intratrach
administr
neonat
mous
lung
fibroblast
result
appar
alveolar
interstiti
engraft
engraft
higher
area
elastaseinduc
lung
injuri
recent
demonstr
intratrach
administr
type
alveolar
epitheli
cell
result
rare
engraft
area
injur
lung
bleomycin
administr
rat
notabl
bleomycininjur
rat
receiv
type
cell
less
histolog
injuri
decreas
hydroxyprolin
content
anoth
report
system
administ
skin
fibroblast
transduc
ex
vivo
express
protect
subsequ
lung
injuri
produc
intratrach
endotoxin
administr
rat
result
suggest
lung
injuri
might
amen
varieti
cell
therapi
approach
report
robust
evid
engraft
suggest
potenti
role
fusion
yet
fulli
elucid
bone
marrowderiv
cell
induc
fuse
lung
epitheli
cell
vitro
initi
vivo
investig
transgen
mous
model
suggest
fusion
occur
recent
report
suggest
fusion
donorderiv
marrow
cell
type
alveolar
epitheli
cell
occur
mous
lung
chromosom
may
lost
result
heterokaryon
cell
mechan
circul
system
administ
stem
progenitor
cell
might
recruit
lung
remain
poorli
understood
system
ie
venou
administr
mani
cell
initi
local
lung
recent
studi
continu
confirm
lung
injuri
result
increas
local
andor
retent
marrowderiv
cell
lung
time
cell
administr
lung
injuri
also
influenc
recruit
phenotyp
convers
system
administr
msc
hour
lung
irradi
result
appar
engraft
ment
cell
epitheli
vascular
endotheli
cell
howev
msc
administ
later
time
point
appear
engraft
interstiti
cell
particip
develop
fibrosi
recipi
immun
respons
also
play
signific
yet
poorli
character
role
retent
cell
lung
commonli
use
approach
sexmismatch
transplant
cell
administr
may
also
result
clearanc
cell
rang
ident
chemotact
solubl
mediat
releas
injur
lung
cell
role
upregul
adhes
molecul
circul
cell
might
interact
remain
poorli
understood
review
refer
refer
engraft
number
factor
includ
age
donor
recipi
type
cell
administ
rout
administr
forth
might
affect
recruit
lung
compar
mechan
stem
progenitor
cell
might
induc
acquir
phenotyp
lung
epitheli
interstiti
vascular
endotheli
cell
remain
poorli
understood
vitro
studi
continu
demonstr
solubl
factor
releas
lung
epitheli
cell
injur
lung
homogen
induc
express
lung
epitheli
marker
sever
type
marrowderiv
cell
possibl
activ
bcatenin
signal
pathway
one
novel
mechan
induc
phenotyp
chang
might
involv
releas
membranederiv
microvesicl
recent
appreci
mean
intercellular
commun
involv
horizont
transfer
mrna
protein
cell
endotheli
progenitor
cell
past
decad
circul
bone
marrowderiv
cell
similar
embryon
angioblast
identifi
term
endotheli
progenitor
cell
cell
potenti
prolifer
differenti
matur
endotheli
cell
increas
evid
demonstr
epc
play
role
pathogenesi
wide
varieti
lung
diseas
includ
pulmonari
hypertens
pulmonari
fibrosi
airway
diseas
includ
asthma
chronic
obstruct
pulmonari
diseas
copd
acut
lung
injuri
lung
cancer
howev
studi
epc
lung
diseas
hamper
lack
consensu
regard
identif
cell
earli
investig
reli
almost
exclus
use
flow
cytometri
conjunct
immunostain
identifi
enumer
cell
bone
marrow
well
circul
furthermor
similar
techniqu
use
differ
report
differ
group
marker
use
complic
compar
assess
similar
diseas
process
result
field
begin
encourag
use
function
assay
vitro
vivo
conjunct
use
flow
cytometri
immunohistochemistri
enumer
epc
better
character
true
abil
form
function
endothelium
critic
area
futur
studi
develop
consensusbas
approach
definit
use
epc
particular
emphasi
function
capabl
cell
recent
develop
character
epc
observ
two
major
type
cell
human
peripher
blood
first
term
earli
epc
character
earli
growth
vitro
posit
inabl
form
tube
matrigel
tubeform
assay
high
level
cytokin
secret
type
epc
term
late
outgrowth
epc
outgrowth
endotheli
cell
character
posit
better
abil
form
tube
either
without
human
umbil
vein
endotheli
cell
cocultur
low
level
cytokin
secret
cell
type
may
uniqu
potenti
lung
microvascular
repair
earli
epc
role
paracrin
cell
late
epc
function
specif
restor
vascular
structur
lung
intraven
infus
type
cell
anim
model
shown
abil
preferenti
local
lung
addit
preliminari
evid
exist
two
epc
type
infus
togeth
may
synergist
role
restor
vascular
structur
function
character
two
epc
type
includ
method
enhanc
number
ex
vivo
could
implic
develop
therapi
specif
phenotyp
abnorm
given
lung
diseas
number
circul
epc
correl
varieti
clinic
variabl
sever
lung
diseas
state
demonstr
potenti
util
epc
biomark
although
increas
circul
epc
number
correl
surviv
acut
lung
injuryacut
respiratori
distress
syndrom
ard
figur
associ
less
residu
lung
damag
patient
pneumonia
increas
number
necessarili
correl
better
outcom
normal
physiolog
lung
diseas
exampl
increas
number
circul
epc
patient
copd
associ
abnorm
spirometri
although
differ
studi
show
level
circul
epc
invers
correl
copd
diseas
sever
increas
number
circul
epc
also
portend
wors
surviv
among
nonsmal
cell
lung
cancer
asthma
number
circul
epc
increas
compar
nonasthmat
control
correl
clinic
outcom
sever
clinic
factor
implic
mobil
epc
mechan
effect
begun
elucid
hypoxia
appear
stimulu
epc
mobil
recruit
wherea
hyperoxia
correl
decreas
circul
epc
featur
may
play
role
bronchopulmonari
dysplasia
prematur
infant
neonat
expos
high
oxygen
level
also
suggest
epc
could
contribut
lung
repair
acut
lung
injuri
defect
lung
develop
defect
lung
repair
set
protract
inflamm
injuri
may
result
part
inadequ
contribut
local
circul
epc
age
previous
report
invers
correl
epc
number
newer
data
suggest
also
differ
abil
epc
home
ischem
tissu
base
age
may
mediat
inabl
age
tissu
normal
activ
hypoxiainduc
hypoxia
respons
use
hmgcoa
coenzym
reductas
inhibitor
previous
shown
benefici
effect
mobil
epc
recent
vitro
work
demonstr
may
relat
effect
class
drug
prevent
epc
apoptosi
respons
noxiou
stimuli
includ
effect
tumor
necrosi
factor
tnf
therebi
enhanc
epc
surviv
differenti
factor
other
may
simultan
exist
patient
lung
diseas
make
incumb
investig
perform
larger
clinic
studi
epc
specif
lung
diseas
use
welldefin
patient
popul
account
effect
number
function
epc
goal
increas
number
epc
develop
method
enhanc
mobil
may
appropri
diseas
affect
lung
particularli
lung
cancer
epc
may
effect
develop
lung
tumor
vasculatur
home
site
lung
metastas
well
cancer
howev
enumer
epc
could
use
marker
lung
cancer
sever
follow
respons
therapi
exampl
increas
level
circul
epc
found
correl
worsen
outcom
patient
nonsmal
cell
lung
cancer
neovascular
involv
recruit
epc
bone
marrow
cell
logic
target
antiangiogenesi
therapi
recent
investig
drug
tk
kringl
domain
tissuetyp
plasminogen
activ
demonstr
use
block
adhes
differenti
migrat
ex
vivo
human
epc
epc
coimplant
cell
nude
mice
tumor
growth
vascular
densiti
increas
tk
treatment
anim
result
decreas
tumor
growth
vascular
decreas
express
secret
vascular
endotheli
growth
factor
vegf
epc
find
suggest
block
epc
could
import
therapi
prevent
cancer
progress
addit
system
inject
epc
local
lung
also
appear
home
metastat
tumor
lung
yet
poorli
understood
mechan
suggest
modif
epc
express
suicid
gene
therapeut
molecul
could
potenti
use
cellbas
therapi
approach
lung
cancer
mechan
control
mobil
home
epc
lung
remain
poorli
understood
subject
intens
investig
earlier
studi
mice
dog
also
demonstr
role
exogen
administ
epc
vasculogenesi
vascular
repair
experiment
model
pulmonari
hypertens
furthermor
epc
transduc
express
proangiogen
factor
endotheli
nitric
oxid
synthetas
eno
inhibitor
smooth
muscl
cell
prolifer
calcitonin
generel
peptid
appear
home
site
endotheli
damag
lung
injuri
epc
also
preferenti
local
area
injur
lung
system
administr
pilot
trial
autolog
epc
administr
primari
pulmonari
hypertens
conduct
zhejiang
univers
hangzhou
china
demonstr
increas
sixminutewalk
capac
improv
hemodynam
variabl
includ
mean
pulmonari
arteri
pressur
pulmonari
vascular
resist
cardiac
output
week
system
administr
autolog
epc
convent
therapi
n
compar
patient
receiv
convent
therapi
alon
n
importantli
advers
effect
epc
administr
note
although
longterm
followup
pend
therapeut
trial
administr
autolog
epc
transduc
express
eno
patient
pulmonari
hypertens
pulmonari
hypertens
cell
therapi
phacet
trial
initi
univers
toronto
januari
phacet
trial
complet
enrol
first
dose
panel
three
patient
receiv
total
million
earlygrowth
epc
transfect
overexpress
human
eno
inform
courtesi
duncan
stewart
md
frcpc
princip
investig
phacet
trial
cell
deliveri
procedur
well
toler
safeti
concern
notabl
first
three
patient
show
remark
nearli
reduct
total
pulmonari
vascular
resist
cours
deliveri
period
might
repres
effect
increas
releas
engin
epc
within
pulmonari
microcircul
trial
data
safeti
monitor
board
approv
move
panel
call
total
million
cell
three
divid
dose
day
investig
expect
complet
third
dose
panel
million
cell
provid
suffici
support
move
forward
design
random
control
trial
assess
potenti
efficaci
cell
therapi
approach
pulmonari
arteri
hypertens
pah
circul
fibrocyt
circul
fibrocyt
first
describ
subset
circul
leukocyt
produc
collagen
home
site
inflamm
ident
phenotyp
character
circul
fibrocyt
firmli
establish
cell
describ
cell
surfac
marker
major
histocompat
class
mhc
ii
also
express
type
collagen
fibronectin
circul
fibrocyt
implic
pathogenesi
lung
fibrosi
sever
mous
model
includ
irradi
bleomycininduc
lung
injuri
review
refer
circul
fibrocyt
also
implic
subepitheli
fibrosi
develop
sever
asthma
clinic
bronchiol
obliteran
lung
transplant
patient
sever
chemokin
includ
stromalderiv
factor
sdf
axe
implic
recruit
circul
fibrocyt
fibrot
lung
overal
mechan
fibrocyt
recruit
lung
poorli
understood
similarli
mechan
fibrocyt
induc
undergo
phenotyp
transform
fibroblast
myofibroblast
contribut
fibrogenesi
lung
poorli
understood
although
recent
haptoglobin
cysteinyl
leukotrien
implic
recent
studi
suggest
level
circul
fibrocyt
increas
patient
usual
nonspecif
interstiti
pneumon
figur
although
suggest
small
studi
need
confirm
larger
cohort
dr
bethani
moor
present
unpublish
data
fibrocyt
isol
peripher
blood
patient
idiopath
pulmonari
fibrosi
exhibit
increas
prolif
collagenproduc
capac
togeth
avail
inform
strongli
suggest
role
circul
fibrocyt
fibrot
lung
diseas
offer
potenti
pathway
therapeut
intervent
fibrocyt
also
increasingli
implic
pathogenesi
vascular
remodel
underli
develop
pulmonari
hypertens
hypoxia
potent
stimulu
releas
pulmonari
vascular
endothelium
varieti
factor
serv
recruit
fibrocyt
well
induc
phenotyp
convers
fibroblast
myofibroblast
fibrocyt
make
signific
proport
mononuclear
cell
infiltr
adventitia
media
pulmonari
vessel
rat
calf
model
hypox
lung
injuri
figur
notabl
deplet
circul
fibrocyt
abrog
hypoxiainduc
perivascular
remodel
rat
result
suggest
specif
inhibit
fibrocyt
use
drug
deliveri
vehicl
may
also
import
therapeut
target
pulmonari
vascular
diseas
circul
fibroblast
precursor
found
blood
patient
lung
cancer
contribut
tumor
develop
system
administ
nod
scid
nonobes
diabeticsever
combin
immunodefici
mice
engraft
human
lung
cancer
xenograft
bone
marrowderiv
cell
may
also
contribut
fibroblast
myofibroblast
tumor
stromal
tissu
may
poorli
understood
properti
fibrocyt
compar
circul
fibroblast
precursor
mesenchym
stem
cell
msc
cell
stromal
origin
selfrenew
abil
differenti
varieti
cell
lineag
initi
describ
popul
bone
marrow
stromal
cell
first
describ
fibroblast
colonyform
unit
subsequ
marrow
stromal
cell
msc
recent
multipot
mesenchym
stromal
cell
msc
msc
isol
wide
varieti
tissu
includ
umbil
cord
blood
wharton
jelli
placenta
adipos
tissu
recent
msc
isol
adult
mous
lung
lung
neonat
lung
transplant
recipi
human
bronchial
fibroblast
also
describ
capabl
exhibit
properti
consist
msc
adult
mous
lung
side
popul
cell
msc
isol
sourc
gener
express
compar
cell
surfac
marker
differenti
along
recogn
lineag
pathway
howev
differ
gene
express
lineag
tendenc
properti
describ
among
msc
isol
differ
sourc
epc
mani
publish
studi
use
differ
definit
character
msc
complic
compar
assess
publish
studi
mesenchym
tissu
stem
cell
committe
intern
societi
cellular
therapi
isct
recent
updat
minim
criteria
defin
human
msc
tabl
hope
rigor
adher
criteria
help
focu
compar
investig
potenti
util
lung
diseas
nonetheless
field
remain
complex
msc
characterist
chang
cultur
condit
microenviron
furthermor
grow
evid
msc
heterogen
differ
msc
subtyp
exist
msc
induc
vitro
express
phenotyp
marker
airway
andor
alveolar
epitheli
cell
engraft
fuse
airway
andor
alveolar
epithelium
interstitium
vascular
endothelium
vivo
system
administr
review
refer
discuss
engraft
gener
rare
although
mani
variabl
remain
explor
nonetheless
increas
number
studi
demonstr
function
role
msc
rodent
model
acut
lung
inflamm
fibrosi
absenc
signific
lung
engraft
intratrach
administr
system
administr
msc
immedi
intratrach
bleomycin
administr
decreas
subsequ
lung
collagen
accumul
fibrosi
level
matrix
metalloproteinas
secret
receptor
antagonist
msc
hypothes
account
least
effect
intratrach
administr
msc
hour
intratrach
endotoxin
administr
decreas
mortal
tissu
inflamm
concentr
proinflammatori
mediat
tnfa
macrophag
inflammatori
protein
mip
bronchoalveolar
lavag
fluid
compar
endotoxinonli
treat
mice
figur
system
msc
administr
also
decreas
lung
inflamm
endotoxin
administr
mice
notabl
transduct
msc
express
decreas
endotoxinmedi
lung
injuri
presum
abrog
endotoxinmedi
endotheli
injuri
howev
system
administr
skin
fibroblast
transduc
express
also
decreas
acut
endotoxininduc
lung
injuri
suggest
varieti
cell
type
might
use
cell
therapi
approach
acut
lung
injuri
cocultur
msc
lung
cell
obtain
lpstreat
mice
result
decreas
proinflammatori
cytokin
releas
lung
cell
lung
injuri
msc
decreas
pulmonari
hypertens
manifest
monocrotalin
mct
induc
pulmonari
vascular
injuri
system
administr
heterogen
popul
autolog
adiposederiv
stromal
cell
decreas
manifest
elastaseinduc
emphysema
rat
hepatocyt
growth
factor
secret
stromal
cell
postul
potenti
mechan
injuri
repair
report
result
suggest
msc
signific
immunomodulatori
effect
lung
absenc
signific
engraft
although
mechan
occur
larg
unknown
howev
grow
inform
suggest
sever
possibl
action
msc
figur
msc
produc
wide
varieti
solubl
mediat
influenc
specif
microenviron
releas
differ
pattern
mediat
exampl
msc
bone
marrow
secret
cytokin
growth
factor
support
hematopoeit
cell
prolifer
develop
includ
gcsf
scf
lif
mcsf
stimul
msc
proinflammatori
cytokin
enhanc
bone
marrow
hematopoeisi
increas
secret
gcsf
mcsf
cultur
system
msc
maintain
ex
vivo
influenc
releas
cytokin
inflammatori
molecul
exampl
cultur
msc
threedimension
hyaluronan
scaffold
increas
releas
matrix
compar
standard
tissu
cultur
wherea
cultur
hypox
condit
synthet
fibrou
matrix
increas
fibronectin
express
matrix
stiff
also
affect
differenti
msc
figur
also
probabl
releas
inflammatori
mediat
msc
influenc
type
inflammatori
environ
found
differ
condit
lung
injuri
review
refer
msc
express
wide
varieti
chemokin
cytokin
receptor
includ
tnfa
ifng
well
sever
tolllik
receptor
includ
endotoxin
receptor
receptor
particular
express
high
abund
recent
describ
prolif
stimulu
msc
stimul
ifng
alter
express
mhc
costimulatori
molecul
msc
nonetheless
effect
msc
secret
solubl
mediat
cytokin
chemokin
microenviron
condit
found
lung
injuri
less
well
explor
msc
also
inhibit
prolifer
function
broad
rang
immun
cell
includ
cell
b
cell
natur
killer
nk
cell
dendrit
cell
figur
notabl
msc
inhibit
tlymphocyt
prolifer
activ
cytokin
releas
respons
either
alloantigen
mitogen
stimuli
dosedepend
direct
suppress
effect
prolifer
mechan
msc
inhibit
tcell
prolifer
function
vitro
partli
understood
direct
cellcel
contact
well
releas
solubl
mediat
propos
furthermor
msc
constitut
express
low
level
hla
class
molecul
express
hla
class
ii
molecul
costimulatori
molecul
essenti
activ
tlymphocytemedi
immun
respons
properti
render
msc
gener
nonimmunogen
basi
sever
clinic
report
recent
clinic
trial
use
autolog
allogen
msc
immunemedi
diseas
gvhd
crohn
diseas
discuss
jane
onken
workshop
trial
demonstr
efficaci
safeti
msc
administr
otherwis
treatmentresist
patient
crohn
diseas
importantli
signific
advers
effect
observ
result
suggest
administr
msc
may
safe
feasibl
clinic
approach
immunemedi
lung
diseas
msc
also
increasingli
describ
vehicl
deliveri
therapeut
gene
protein
notabl
msc
home
tumor
yet
unclear
mechan
serv
vehicl
deliveri
chemotherapeut
antitumor
agent
recent
describ
mous
lung
tumor
model
may
provid
viabl
therapi
lung
cancer
contrast
msc
may
also
contribut
tumor
stroma
influenc
behavior
cancer
cell
whether
marrowderiv
cell
contribut
develop
epitheli
cancer
remain
activ
area
investig
addit
caution
regard
system
administr
msc
rais
cultur
strategi
use
fetal
bovin
calf
serum
despit
wash
cell
system
administr
bovin
antigen
may
remain
adher
cell
surfac
trigger
immun
reaction
well
decreas
potenti
engraft
recipi
mice
patient
cultur
msc
medium
lower
calf
serum
content
use
heterolog
speciesspecif
serum
altern
serum
substitut
platelet
lysat
remov
calf
serum
antigen
administr
propos
strategi
decreas
potenti
advers
effect
addit
intraven
administr
msc
initi
lodg
lung
vasculatur
move
pulmonari
capillari
system
organ
howev
depend
prepar
regimen
use
msc
clump
potenti
lodg
emboli
lung
capillari
pretreat
mice
vasodil
sodium
nitroprussid
propos
mechan
decreas
cell
trap
msc
pulmonari
capillari
furthermor
develop
lung
sarcoma
system
administ
msc
describ
interestingli
describ
administr
mous
human
msc
may
reflect
greater
propens
mous
msc
acquir
chromosom
abnorm
serial
passag
cultur
howev
extens
cultur
almost
mammalian
cell
cultur
lead
crisi
follow
immort
transform
tumorigen
cell
well
document
mous
fibroblast
murin
msc
extens
expand
cultur
mani
passag
develop
chromosom
instabl
produc
lung
sarcoma
mice
human
msc
cultur
month
underw
similar
chang
anticip
addit
strategi
maxim
therapeut
util
msc
decreas
chanc
advers
effect
develop
next
sever
year
lung
tissu
bioengin
one
grow
area
investig
util
threedimension
matric
artifici
scaffold
growth
function
lung
tissu
stem
cell
ex
vivo
vivo
approach
increasingli
success
use
regener
tissu
includ
skin
vasculatur
cartilag
bone
given
complex
threedimension
architectur
lung
daunt
task
nonetheless
signific
progress
sever
area
notabl
msc
isol
amniot
fluid
umbil
cord
blood
bone
marrow
seed
biodegrad
polyglycol
acid
biosynthet
scaffold
gener
tracheal
cartilag
use
repair
congenit
tracheal
defect
also
tendon
tissu
use
congenit
diaphragmat
defect
notabl
extracellular
matrix
properti
cartilag
depend
sourc
msc
data
present
dr
fauza
confer
preclin
studi
largeanim
model
sheep
suggest
safeti
efficaci
clinic
trial
neonat
congenit
tracheal
diaphragmat
defect
plan
threedimension
cultur
system
also
use
matric
ex
vivo
lung
parenchym
develop
studi
growth
factor
mechan
forc
lung
remodel
cultur
fetal
rat
lung
suspens
threedimension
glycosaminoglycan
gag
scaffold
result
format
alveolarlik
structur
scaffold
fetal
mous
cell
cultur
threedimension
hydrogel
synthet
polym
scaffold
result
gener
alveolarlik
unit
notabl
stimul
fetal
mous
cell
polym
scaffold
differ
isoform
fibroblast
growth
factor
stimul
differ
pattern
develop
demonstr
power
threedimension
cultur
system
evalu
lung
develop
repair
vivo
recent
studi
demonstr
fetal
rat
lung
cell
cultur
biosynthet
gelatin
matrix
subsequ
inject
normal
rat
lung
induc
format
branch
saccul
epitheli
structur
reminisc
lung
parenchym
architectur
figur
howev
studi
yet
evalu
whether
stem
progenitor
cell
isol
adult
bone
marrow
cord
blood
sourc
also
compar
form
airway
alveolarlik
structur
cultiv
threedimension
matrix
scaffold
materi
furthermor
whether
stem
progenitor
cell
cultur
fashion
use
function
lung
regener
vivo
popul
cell
describ
adult
lung
somat
progenitor
cell
isol
adult
sheep
lung
cultur
synthet
polym
construct
result
express
airway
alveolar
epitheli
marker
cell
structur
resembl
lung
airway
parenchyma
develop
impregn
construct
implant
subcutan
nude
mice
insert
wound
caviti
wedg
lung
resect
sheep
adiposederiv
msc
cultur
ex
vivo
sheet
polyglycol
acid
appli
wound
edg
lung
volum
reduct
surgeri
rat
acceler
alveolar
vascular
regener
sever
abstract
present
workshop
also
present
american
thorac
societi
intern
confer
begun
explor
question
lung
tissu
bioengin
stem
cell
project
area
intens
investig
endogen
tissu
stem
cell
undifferenti
cell
identifi
nearli
tissu
believ
contribut
tissu
mainten
repair
rare
unspeci
cell
often
local
special
nich
within
tissu
usual
cycl
infrequ
cell
exhibit
selfrenew
capacitythey
produc
unspeci
cellsand
also
give
rise
daughter
cell
known
progenitor
cell
transitamplifi
cell
progenitor
cell
finit
life
span
higher
rate
prolifer
compar
stem
cell
stem
progenitor
cell
may
give
rise
special
differenti
cell
organ
howev
signific
terminolog
problem
exist
endogen
stem
cell
progenitor
cell
type
context
progenitor
cell
use
describ
cell
robust
prolif
potenti
toxinresist
cell
clara
cell
basal
cell
etc
problem
restrict
lung
exampl
similar
terminolog
issu
occur
intestin
particularli
progenitor
cell
type
differ
organ
differ
properti
regul
glossari
depict
tabl
necessarili
reflect
overal
consensu
definit
term
undergo
continu
revis
overal
understand
cell
type
mechan
involv
lung
repair
continu
elucid
nonetheless
use
framework
evid
indic
exist
cellular
compon
airway
epitheli
stem
cell
hierarchi
come
studi
mous
model
select
ablat
epitheli
cell
achiev
exposur
toxic
chemic
cell
typespecif
express
toxic
gene
transgen
mice
use
approach
sever
popul
progenitor
cell
properti
tissu
stem
cell
identifi
along
tracheobronchi
tree
figur
trachea
larg
airway
subpopul
basal
epitheli
cell
express
cytokeratin
implic
mice
clara
cell
exhibit
characterist
transitamplifi
cell
injuri
ciliat
airway
epitheli
cell
howev
unlik
transitamplifi
cell
tissu
higher
rate
epitheli
turnov
intestin
clara
cell
exhibit
low
prolif
frequenc
steadi
state
broadli
distribut
throughout
bronchiolar
epithelium
contribut
special
tissu
function
distal
airway
toxin
ie
naphthalen
resist
variant
clara
cell
identifi
stem
cell
function
term
bronchiolar
stem
cell
naphthaleneresist
cell
also
locat
within
discret
microenviron
within
bronchiol
includ
neuroepitheli
bodi
bronchoalveolar
duct
junction
badj
badj
mous
lung
popul
naphthaleneresist
cell
stain
ccsp
prosurfact
protein
c
prospc
describ
although
rare
cell
found
prolifer
respons
naphthalen
injuri
furthermor
prospcccsp
dual
posit
cell
isol
use
method
develop
enrich
type
alveolar
epitheli
cell
duallabel
cell
exhibit
uniqu
cell
surfac
phenotyp
po
po
neg
neg
cell
found
selfrenew
cultur
give
rise
progeni
express
ccsp
prospc
aquaporin
cell
term
bronchioalveolar
stem
cell
basc
howev
whether
properti
cell
vitro
also
appli
vivo
unknown
possibl
toxinresist
clara
cell
basc
cell
may
repres
differ
interpret
cell
popul
highlight
need
rigor
method
lineag
trace
well
underscor
import
vivo
microenviron
cell
behavior
although
sever
signal
pathway
includ
wnt
hedgehog
notch
implic
stem
cell
function
tissu
remain
pauciti
understand
key
element
establish
maintain
adult
lung
tissu
recent
investig
begun
clarifi
cell
signal
regulatori
mechan
regul
put
lung
progenitor
popul
exampl
tumorigen
insult
includ
delet
mitogenactiv
protein
kinas
delet
oncogen
mutat
shown
induc
expans
ccspprospc
duallabel
badj
cell
number
also
enhanc
lung
tumorigenesi
howev
precis
role
pathway
endogen
lung
stem
progenitor
cell
remain
determin
recent
anoth
popul
put
progenitor
cell
express
ccsp
stem
cell
antigen
sca
stagespecif
embryon
antigen
ssea
es
cell
marker
identifi
neonat
mice
cell
abl
form
epitheli
coloni
differenti
type
type
alveolar
epitheli
cell
interestingli
cell
suscept
infect
sar
sever
acut
respiratori
syndrom
viru
rais
possibl
endogen
lung
progenitor
cell
may
specif
diseas
target
endogen
progenitor
cell
may
also
attract
candid
target
gene
transfer
vector
provid
sustain
express
possibl
remain
endogen
stem
progenitor
popul
exist
much
room
addit
inform
regulatori
mechan
pathway
elucid
epitheli
progenitor
cell
popul
less
inform
avail
differ
endogen
stem
progenitor
cell
differ
clinic
lung
diseas
airway
epithelium
patient
cystic
fibrosi
cf
contain
primit
cuboid
cell
express
primit
cell
marker
includ
thyroid
transcript
factor
cytokeratin
neuroepitheli
cell
also
express
cf
transmembran
conduct
regul
cftr
appear
play
role
neuropeptid
secret
cftr
knockout
mice
also
contain
fewer
pulmonari
neuroendocrin
cell
embryon
develop
increas
number
cell
postnat
suggest
endogen
progenitor
cell
pathway
cf
lung
may
alter
extens
investig
addit
role
endogen
lung
stem
progenitor
cell
repair
lung
injuri
increas
inform
suggest
matur
differenti
lung
cell
may
transdifferenti
chang
phenotyp
best
describ
epithelialmesenchym
transit
recent
investig
describ
wider
rang
revers
phenotyp
epitheli
mucu
cell
mechan
may
also
play
signific
role
injuri
repair
injuri
overal
remain
much
learn
endogen
stem
lung
progenitor
cell
includ
clarif
human
counterpart
cell
identifi
mous
model
furthermor
rel
littl
known
behavior
endogen
stem
progenitor
cell
clinic
lung
diseas
model
lung
cancer
stem
cell
intens
current
interest
connect
endogen
stem
progenitor
cell
cancer
stem
cell
cancer
stem
cell
defin
transplant
assay
critic
cell
tumor
capabl
propag
diseas
hypothes
cell
maintain
tumor
progress
diseas
resist
although
cancer
stem
cell
describ
breast
solid
cancer
exist
lung
cancer
stem
cell
cell
less
well
establish
basc
suggest
role
develop
lung
cancer
mice
role
tumor
maintan
establish
human
correl
demonstr
recent
studi
shown
cell
cultur
lung
cancer
cell
primari
lung
tumor
exhibit
abil
propag
lung
cancer
inject
subcutan
mice
side
popul
hoechstefflux
cell
also
recent
identifi
sever
human
lung
cancer
cell
line
exhibit
tumorigen
properti
subcutan
implant
nod
scid
mice
side
popul
cell
also
identifi
clinic
lung
cancer
specimen
howev
despit
suggest
data
two
report
work
need
clarifi
connect
endogen
lung
stem
cell
cell
origin
cancer
cancer
stem
cell
determin
potenti
role
therapeut
target
recent
studi
begun
elucid
cell
signal
gene
express
pathway
includ
wnt
hedgehog
other
may
play
role
transform
endogen
progenitor
cell
cancer
cell
addit
bone
marrowderiv
circul
msc
hsc
epc
fibrocyt
may
contribut
develop
lung
malign
mous
model
part
provid
support
stroma
cancer
andor
particip
tumor
vascular
howev
msc
epc
demonstr
home
area
tumor
develop
engin
epc
msc
well
hsc
use
suppress
tumor
growth
mous
tumor
model
cellbas
therapi
may
thu
use
lung
cancer
therapeut
mous
es
cell
induc
cultur
express
prosurfact
b
marker
type
alveolar
epitheli
cell
furthermor
exposur
mous
es
cell
dissoci
fetal
lung
cell
induc
pseudoglandular
format
prospc
express
one
notabl
studi
mous
es
cell
cultur
airliquid
interfac
form
pseudostratifi
epithelium
resembl
mous
tracheal
epithelium
studi
demonstr
capac
es
cell
acquir
airway
epitheli
phenotyp
vitro
compar
studi
human
es
cell
remain
limit
due
current
restrict
human
es
cell
use
particularli
unit
state
nonetheless
recent
demonstr
cell
one
approv
human
es
line
unit
state
induc
vitro
express
phenotyp
characterist
type
alveolar
epitheli
cell
figur
compar
studi
england
also
demonstr
induct
prospc
express
cultur
human
es
cell
recent
studi
australia
compar
mous
human
es
cell
expos
dissoci
fetal
lung
cell
found
sever
differ
pattern
lung
gene
express
at
issu
statement
call
expand
human
es
cell
research
anticip
human
es
cell
research
expand
unit
state
next
sever
year
human
embryon
stem
cell
line
establish
england
anoth
describ
belgium
cell
exhibit
normal
morpholog
protein
express
compar
es
cell
line
studi
detail
recent
descript
induct
pluripot
adult
skin
fibroblast
adult
cell
type
offer
anoth
possibl
gener
lung
cell
autolog
somat
cell
particular
might
possibl
gener
induc
pluripot
cell
line
lung
patient
model
diseas
workshop
organ
four
oral
present
session
one
poster
present
session
goal
present
provid
stateoftheart
summari
exist
inform
highlight
question
address
futur
research
direct
summari
oral
present
provid
execut
summari
speaker
present
poster
abstract
present
accompani
onlin
supplement
goal
session
review
current
state
knowledg
endogen
stem
cell
popul
lung
role
lung
develop
role
nich
microenviron
lung
progenitor
cell
session
began
dian
kraus
yale
univers
school
medicin
provid
gener
overview
stem
cell
highlight
although
mani
cell
refer
stem
cell
differenti
multipl
cell
type
true
stem
cell
capabl
extens
selfrenew
wherea
progenitor
found
differ
special
region
lung
limit
capac
control
differenti
determin
part
cell
respons
microenvironment
nich
contain
cue
tension
extracellular
matrix
compon
dr
kraus
discuss
differ
endogen
lung
progenitor
includ
basal
cell
submucos
gland
proxim
airway
clara
cell
clara
cell
variant
ccsp
spc
found
bronchoalveolar
duct
junction
conduct
airway
type
ii
pneumocyt
alveolar
progenitor
capac
extrapulmonari
precursor
deriv
bone
marrow
becom
pulmonari
epitheli
cell
describ
use
establish
male
femal
bone
marrow
transplant
mous
model
system
togeth
histochem
analys
requir
demonstr
engraft
pulmonari
differenti
donor
cell
sever
multipot
bone
marrow
subpopul
engraft
becom
epitheli
cell
probabl
differ
mechan
abund
evid
demonstr
tissu
damag
induc
irradi
requir
bone
marrowderiv
epitheli
engraft
cell
appear
function
shown
cftr
spc
mous
experi
defici
gene
express
partial
restor
lung
mani
mechan
plastic
adult
stem
cell
propos
includ
differenti
direct
indirect
transdifferenti
fusion
combin
thereof
discrep
literatur
part
due
differ
type
sever
lung
injuri
induc
provid
home
signal
differ
assay
use
determin
stem
eg
label
retent
retrovirus
transgen
report
system
cell
ablat
techniqu
fact
differ
laboratori
use
differ
marker
identifi
isol
precursor
cell
area
certainli
need
address
futur
issu
need
address
includ
definit
prolif
differenti
activ
stemprecursor
cell
differ
region
adult
lung
develop
improv
method
transplant
track
cell
vivo
improv
isol
valid
cell
identif
critic
nich
compon
lead
better
engraft
differenti
determin
risk
exogen
cell
administr
develop
safe
effect
treatment
promot
lung
progenitor
function
wellington
cardoso
boston
univers
school
medicin
discuss
role
specif
pathway
development
program
lung
progenitor
cell
earli
program
may
relev
adult
lung
regenerationrepair
identif
critic
factor
program
may
use
design
develop
treatment
lung
diseas
key
understand
signal
provid
nich
context
need
deliv
mous
studi
describ
identif
earli
pulmonari
progenitor
embryo
review
transcript
factor
label
lung
progenitor
foregut
endoderm
format
lung
bud
import
transcript
factor
eg
lung
epitheli
develop
lung
homeostasi
discuss
dr
cardoso
underscor
critic
role
fibroblast
growth
factor
receptor
signal
via
expans
earli
lung
progenitor
format
lung
primordium
present
data
target
tumorassoci
calcium
signal
transduc
cathepsin
h
branch
morphogenesi
discuss
control
bone
morphogenet
protein
bmp
pathway
maintain
epitheli
surviv
also
present
evid
act
protooncogen
transgen
mice
express
lung
epithelium
develop
multipl
pulmonari
tumor
potent
induc
express
epitheli
progenitor
structur
includ
lung
well
mani
epitheli
cancer
may
play
role
injuri
repair
process
induc
bronchial
epitheli
cell
expos
pseudomona
renal
regener
repair
import
retino
acid
ra
lung
progenitor
cell
expans
inhibit
transform
growth
factor
tgf
b
pathway
induct
potenti
role
ra
alveolar
lung
injuri
repair
review
lesson
lung
develop
need
integr
regener
strategi
induct
signal
trigger
specif
differenti
program
need
identifi
context
time
posit
cue
investig
also
need
identifi
physic
properti
cell
local
microenviron
vi
mechan
forc
bioelectr
ie
correct
microenviron
need
recreat
strategi
technolog
character
molecular
signatur
develop
adult
lung
compon
need
develop
studi
integr
genet
development
bioengin
aspect
lung
need
design
use
biolog
relev
model
system
dr
rick
wetsel
univers
texashouston
describ
deriv
type
ii
alveolar
epitheli
cell
one
human
es
cell
line
embryon
bodi
format
requir
contrast
previous
document
ann
bishop
lab
use
mous
es
cell
dr
wetsel
protocol
entail
use
matrigel
plate
select
cell
spc
lamellar
bodi
molecular
analysi
show
cell
express
cftr
surfact
protein
b
c
antitrypsin
complement
compon
incub
cell
express
alveolar
type
cell
marker
preliminari
data
also
shown
demonstr
human
esderiv
alveolar
type
ii
cell
could
amelior
bleomycininduc
lung
injuri
mice
indic
potenti
therapeut
use
cell
barri
stripp
duke
univers
medic
center
review
current
state
knowledg
hierarchi
stem
cell
progeni
adult
tissu
comparison
made
bronchiolar
stem
cell
classic
stem
cell
hierarchi
hematopoiet
system
intestin
classic
hierarchi
consist
infrequ
cycl
cell
rapidli
divid
transitamplifi
ta
progeni
ta
cell
vari
organ
abund
differenti
potenti
equival
stem
cell
cycl
frequent
finit
prolif
capac
contrast
lung
exhibit
nonclass
hierarchi
ta
cell
eg
clara
cell
cycl
infrequ
differenti
phenotyp
prolif
capac
unknown
anatom
site
nich
differ
stemprogenitor
cell
lung
discuss
comparison
also
made
stem
cell
nich
tissu
role
asymmetr
cell
divis
adheren
junction
complex
mainten
stem
cell
pool
eg
intestin
crypt
hair
follicl
bone
marrow
subventricular
zone
brain
dr
stripp
review
data
demonstr
exist
latent
bronchiolar
tissuespecif
stem
cell
role
airway
repair
ablat
clara
cell
administr
naphthalen
allow
identif
distal
airway
stem
cell
resist
naphthalen
local
two
discret
microenviron
neuroepitheli
bodi
badj
experi
show
bcatenin
stabil
truncat
nterminu
bcatenin
alter
phenotyp
clara
cell
increas
prolifer
potenti
airway
day
naphthalen
injuri
b
stripp
unpublish
data
mani
fundament
issu
idea
remain
address
includ
relationship
development
progenitor
cell
adult
tissu
stem
cell
whether
lung
tissu
stem
cell
requir
postnat
constitu
stem
cell
nich
nich
chang
set
chronic
acut
lung
diseas
strategi
replic
replac
stem
cell
nich
need
develop
cellbas
therapeut
approach
anoth
challeng
defin
relationship
normal
repair
versu
tissu
remodel
ivan
bertoncello
australian
stem
cell
center
describ
local
microenviron
lung
interact
endogen
lung
stem
cell
specifi
fate
modul
cell
surfac
phenotyp
stem
cell
exist
state
dynam
reciproc
microenviron
reciproc
signal
stem
cell
extracellular
matrix
support
stromal
cell
accessori
cell
mediat
solubl
insolubl
factor
regul
regen
potenti
steadi
state
respons
injuri
dr
bertoncello
emphas
stem
cell
defin
oper
rather
decor
evid
far
show
stem
cell
multipli
mark
common
stem
cellassoci
marker
includ
membran
transport
protein
confer
hoechst
side
popul
phenotyp
restrict
singl
cell
lineag
typic
share
variabl
express
cell
differ
development
potenti
activ
state
matur
age
whether
marker
defin
put
bronchioalveolar
stemprogenitor
cell
clear
need
valid
robust
vitro
vivo
function
assay
literatur
far
suggest
exist
discret
stemprogenitor
cell
along
proximaldist
axi
lung
stemprogenitor
cell
locat
submucos
gland
give
rise
upper
airway
epithelium
express
locat
neuroepitheli
bodi
nich
express
ccsp
give
rise
secretori
airway
epithelium
ccsp
prospc
cell
badj
give
rise
alveolar
type
ii
type
pneumocyt
advanc
understand
organ
lung
stemprogenitor
cell
hierarchi
microenvironment
regul
conting
prospect
isol
candid
stem
cell
studi
howev
absenc
uniqu
stem
cell
marker
object
confound
loss
spatial
inform
histomorphometr
cue
dissagreg
lung
lack
function
surrog
assay
accur
measur
development
potenti
regen
capac
data
present
demonstr
emerg
exponenti
expans
cell
neonat
murin
lung
coincid
transit
saccular
alveolar
stage
lung
develop
nonhematopoiet
nonendotheli
cell
compris
heterogen
predominantli
mesenchym
cell
contain
precursor
respiratori
epithelium
stromal
microenviron
coexpress
prospc
give
rise
fibroblastoid
epitheli
cell
cultur
dr
bertoncello
conclud
lesson
learn
delin
hematopoiet
stem
cell
hierarchi
appli
identif
character
lung
stemprogenitor
cell
goldstandard
vivo
assay
requir
valid
vitro
surrog
assay
readout
lung
stem
cell
phenotyp
marker
repertoir
confirm
abil
surrog
assay
predict
regen
potenti
lung
stemprogenitor
cell
perturb
mutant
mous
model
recent
demonstr
gener
function
mammari
gland
singl
orthotop
transplant
mammari
stem
cell
isol
basi
differenti
express
present
exampl
goldstandard
vivo
assay
field
aspir
dougla
ball
john
hopkin
univers
school
medicin
discuss
role
progenitor
cell
lung
cancer
much
overlap
field
lung
cancer
development
biolog
fact
normal
progenitor
cell
subtyp
defin
scope
differenti
phenotyp
lung
cancer
treatment
resist
overrid
issu
clinic
lung
cancer
understand
lung
stem
cell
biolog
key
attack
resist
nich
stem
cell
repertoir
canceriniti
cell
may
alter
initi
genet
epigenet
chang
gene
encod
protein
retinoblastoma
protein
rb
ra
epiderm
growth
factor
receptor
egfr
activ
mutat
egfr
result
rapid
emerg
treatmentresist
form
nonsmal
cell
lung
cancer
evid
show
cell
tumoriniti
potenti
express
marker
lung
progenitor
basc
basc
ccsp
spc
may
cancerpron
progenitor
popul
data
present
show
respond
kra
unlik
atii
cell
naphthalen
airway
injuri
mutat
augment
prolifer
transform
basc
mous
model
lung
cancer
loss
airway
target
clara
cell
basc
induc
basic
helixloophelix
transcript
factor
use
promot
show
progenitor
cell
potenti
lung
carcinoma
give
rise
mix
neuroendocrin
phenotyp
also
interest
cultur
human
nonsmal
cell
lung
cancer
cell
exhibit
side
dye
efflux
phenotyp
cell
increas
tumorform
effici
invas
matrigel
express
higher
level
human
telomeras
revers
transcriptas
htert
exhibit
mark
resist
spectrum
drug
includ
cisplatin
etoposid
gemcitabin
doxorubicin
normal
lung
sp
cell
total
lung
cell
evenli
distribut
proxim
distal
lung
region
posit
posit
posit
neg
furthermor
sp
cell
adult
mous
lung
highli
clonogen
put
marker
lung
cancer
stem
cell
includ
aldehyd
dehydrogenas
shrnamedi
knockdown
experi
decreas
small
cell
lung
cancer
cell
associ
increas
radiosensit
cell
irradi
data
shown
demonstr
g
arrest
reduc
atmdepend
dna
damag
respons
futur
research
clinic
translat
find
requir
robust
panel
marker
character
differ
stage
stem
progenitor
develop
lung
understand
differenti
potenti
progress
restrict
process
preserv
alter
lung
cancer
understand
recogn
earli
progenitor
transitamplifi
differenti
phenotyp
within
complex
tumor
surviv
cell
monitor
primari
treatment
final
understand
distinguish
lung
cancer
progenitor
target
essenti
pathway
normal
renew
tissu
discuss
section
led
dr
carla
kim
children
hospit
boston
sue
reynold
univers
pittsburgh
jeff
spee
univers
vermont
discuss
began
basic
question
lung
stem
cell
term
defin
lung
suggest
includ
follow
cell
reconstitut
entir
organ
cell
suppli
progenitor
repair
injuri
cell
suppli
progenitor
steadi
state
still
major
need
new
method
marker
identifi
track
stem
cell
develop
context
injuri
need
identifi
microenvironment
nich
factor
requir
maintain
stem
critic
reproduc
model
analog
use
hematopoiet
field
consist
lab
establish
use
lung
cancer
stem
cell
identifi
marker
work
backward
may
use
approach
suggest
use
serial
injuri
instead
serial
transplant
use
evalu
regen
capac
lung
stemprogenitor
cell
stratif
hierarch
order
hematopoiet
stem
progenitor
cell
compart
tempor
analysi
hematopoiet
regener
myeloabl
suggest
exampl
power
approach
need
establish
consist
method
use
differ
lab
emphas
phenotyp
cell
isol
differ
respect
digest
protocol
use
eg
collagenas
dispas
pronas
discuss
concern
marker
express
postnat
mous
human
correl
known
also
unclear
whether
aquaporin
marker
human
session
end
express
need
investig
effect
epigenet
compil
methyl
map
relev
lung
stem
cell
field
second
session
eclect
rather
domin
singl
concept
compos
three
loos
relat
topic
first
collect
review
address
mechan
stem
cell
mechan
sens
environ
determin
constitut
appropri
nich
foster
prolifer
differenti
initi
discuss
basic
event
two
talk
concentr
potenti
preclin
approach
facilit
translat
observ
maxim
therapeut
use
deliveri
differenti
endogen
exogen
progenitor
repair
injur
degener
lung
denni
e
discher
univers
pennsylvania
demonstr
like
normal
tissu
cell
stem
cell
anchorag
depend
therefor
abl
surviv
exclus
suspend
fluid
media
stem
cell
determin
stiff
matrix
elus
question
recent
develop
atom
forc
microscopi
avail
cultur
condit
allow
close
regul
elast
resembl
physiolog
condit
possibl
determin
stem
cell
experi
signific
biolog
alter
involv
format
adhes
complex
induct
signal
transduct
lead
alter
actin
myosin
cytoskeleton
contractil
chang
transfer
throughout
transcellular
structur
dr
discher
illustr
import
nonmuscl
myosin
differenti
biolog
stem
cell
point
es
cell
defici
nonmuscl
myosin
ii
express
gener
embryoid
bodi
flaccid
exhibit
function
differenti
similarli
defici
embryon
lethal
day
due
lack
develop
cardiovascular
structur
blood
vessel
heart
cite
previou
literatur
dr
discher
indic
normal
condit
surfac
flexibl
predomin
determin
cell
locomot
therefor
cell
grown
stiffer
substrat
assembl
focal
adhes
demonstr
larger
spread
cultur
softer
flexibl
substrat
matrix
stiff
also
determin
stem
cell
lineag
differenti
thu
naiv
msc
cultur
soft
matric
predominantli
exhibit
neurogen
differenti
wherea
stiffer
matric
induc
myogen
osteogen
differenti
tissu
vari
intrins
flexibl
blood
elast
fluid
wherea
brain
tissu
averag
kpa
found
muscl
bone
higher
possibl
anticip
differenti
potenti
stem
cell
therapeut
purpos
postul
clearli
demonstr
find
show
cultur
human
msc
current
undergo
clinic
trial
substrat
close
resembl
specif
organ
stiff
induc
express
differenti
marker
figur
even
cell
cultur
absenc
specif
induct
factor
principl
fundament
use
stem
cell
treat
lung
diseas
elast
lung
clearli
alter
injuri
ie
increas
lung
fibrosi
degener
dr
mingyao
liu
univers
toronto
share
experi
differ
matrix
effect
mechan
deliv
stem
cell
injur
lung
promot
regener
dr
liu
identifi
threedimension
complex
inher
lung
formid
challeng
tissu
regener
lung
newli
gener
lung
epithelia
need
close
proxim
vascular
structur
assur
appropri
ga
exchang
dr
liu
discuss
current
approach
cellbas
therapi
lung
focus
target
progenitor
area
injuri
need
strategi
base
use
tissuespecif
progenitor
expand
sometim
modifi
cultur
administ
cell
suspens
either
system
intratrach
viabl
altern
introduct
engin
tissu
lung
hope
surviv
graft
subsequ
expans
invas
graft
nativ
cell
approach
logic
requir
use
scaffold
materi
provid
threedimension
matrix
implant
stem
cell
provid
opportun
surround
tissu
cell
migrat
prolifer
foment
product
alveolarlik
structur
subsequ
dr
liu
detail
physic
properti
sever
spongebas
scaffold
demonstr
organotyp
cultur
abil
cell
form
alveolarlik
structur
includ
initi
review
previou
demonstr
lung
alveolar
structur
format
fetal
mous
rat
lung
cell
cultur
synthet
collagen
glycosaminoglycan
polylacticcoglycolicacid
plga
polyllact
acid
plla
scaffold
dr
liu
report
group
experi
univers
toronto
demonstr
gelfoam
spong
fetal
lung
cell
surgic
implant
chest
caviti
rat
surviv
extend
period
time
subsequ
surround
nativ
tissu
cell
migrat
spong
structur
form
alveolarlik
structur
connect
pulmonari
circul
follow
degrad
spong
scaffold
sever
month
origin
implant
figur
third
speaker
dr
dario
fauza
children
hospit
harvard
discuss
group
experi
investig
engin
airway
reconstruct
cartilag
construct
base
msc
detail
studi
abil
msc
amniot
fluid
af
bone
marrow
umbil
cord
blood
group
shown
af
msc
rate
prolifer
twice
one
observ
bone
marrow
cord
blood
msc
three
set
msc
afderiv
msc
highest
concentr
sulfat
glycosaminoglycan
elastin
fact
af
elastin
concentr
high
nativ
elast
cartilag
proteoglycan
concentr
determin
mechan
compress
strength
elastin
flexibl
nativ
elast
cartilag
afderiv
msc
appear
optim
develop
engin
cartilag
use
airway
reconstruct
dr
fauza
point
afbas
msc
easili
obtain
low
volum
fluid
obtain
amniocentesi
ml
produc
suffici
amount
msc
success
engin
cartilag
prepar
although
artifici
engin
cartilag
deplet
epitheli
coverag
implant
would
line
ciliat
pseudostratifi
columnar
epithelium
deriv
host
vivo
second
topic
session
pertain
biolog
circul
fibrocyt
contribut
lung
injuri
remodel
initi
identifi
bucala
cowork
fibrocyt
describ
subset
circul
cell
simultan
exhibit
leukocyt
mesenchym
collagen
iii
well
vimentin
marker
dr
bethani
b
moor
univers
michigan
review
role
cell
play
pathogenesi
lung
fibrosi
dr
moor
point
upon
recruit
injur
lung
fibrocyt
lose
express
leukocyt
marker
enhanc
product
extracellular
matrix
express
inflammatori
mediat
tnf
plateletderiv
growth
factor
pdgf
tgfb
cysteinyl
leukotrien
dr
moor
work
indic
leukotrien
contribut
fibroblast
myofibroblast
differenti
cell
sever
anim
model
lung
fibrosi
bleomycin
fluorescein
isothiocyan
herpesviru
infect
furthermor
dr
moor
data
indic
adopt
transfer
fibrocyt
worsen
sever
experiment
pulmonari
fibrosi
role
circul
fibrocyt
also
implic
pathogenesi
human
lung
injuri
cite
work
schmidt
nihlberg
colleagu
dr
moor
indic
cell
contribut
subepitheli
fibrosi
observ
airway
patient
afflict
sever
allerg
asthma
similarli
number
circul
fibrocyt
increas
figur
patient
usual
nonspecif
interstiti
pneumon
may
contribut
acut
exacerb
observ
patient
taken
togeth
avail
inform
strongli
support
role
circul
fibrocyt
pathogenesi
fibrot
lung
diseas
offer
new
potenti
pathway
therapeut
intervent
dr
kurt
r
stenmark
univers
colorado
health
scienc
center
discuss
data
show
import
role
fibrocyt
pathogenesi
vascular
remodel
observ
develop
pulmonari
hypertens
respons
hypoxia
exposur
neonat
calv
chronic
hypoxia
dr
stenmark
laboratori
observ
robust
accumul
monocyt
fibrocyt
adventitia
media
pulmonari
system
vessel
studi
biolog
fibrocyt
hypox
pulmonari
hypertens
dr
stenmark
laboratori
take
advantag
freemartin
calf
femal
anim
chimer
xxyy
bone
marrow
exposur
freemartin
hypoxia
follow
appear
vimentin
express
ychromosom
cell
adventitia
small
vessel
thu
suggest
bone
marrow
origin
cell
laser
captur
microdisect
studi
show
timedepend
increas
vegf
intercellular
adhes
molecul
icam
vascular
cell
ahes
molecul
vcam
mediat
chemoattract
prolif
activ
properti
dr
stenmark
also
present
data
indic
deplet
circul
fibrocyt
nearli
abrog
hypoxiainduc
vascular
remodel
rat
therefor
case
fibrot
lung
diseas
result
also
identifi
fibrocyt
import
player
vascular
patholog
suggest
physic
pharmacolog
inhibit
cell
may
constitut
import
therapeut
option
treatment
pulmonari
vascular
diseas
final
lectur
second
section
dr
johnni
huard
univers
pittsburgh
discuss
role
musclederiv
stem
cell
potenti
sourc
regen
medicin
similar
achiev
bone
marrow
dr
huard
indic
laboratori
identifi
base
adhes
prolifer
stem
cell
marker
express
sever
popul
myogen
cell
skelet
muscl
adult
mice
one
popul
cell
particular
exhibit
selfrenew
differenti
potenti
cell
term
musclederiv
stem
cell
transplant
musclederiv
stem
cell
myogen
cell
improv
regener
dystroph
muscl
effici
deliv
dystrophin
protein
defici
muscl
cell
effect
signific
femalerath
malederiv
cell
use
dr
huard
indic
mechan
respons
differ
gender
effici
among
musclederiv
stem
cell
complet
understood
may
involv
better
inhibit
tgfb
signal
transduct
final
dr
huard
review
data
suggest
musclederiv
stem
cell
could
engin
express
osteogen
protein
vegf
properti
laboratori
use
success
promot
cartilag
bone
heal
discuss
section
led
dr
zea
borok
univers
southern
california
ed
ingenito
harvard
medic
school
darrel
kotton
boston
univers
eclect
natur
talk
section
discuss
broad
sens
audienc
opinion
constitut
ideal
stem
cell
type
use
clinic
trial
although
definit
conclus
achiev
overwhelm
consensu
msc
endotheli
progenitor
offer
best
prospect
use
human
trial
lung
injuri
regener
final
repres
particip
patient
advoc
group
remind
audienc
immediaci
need
encourag
immedi
launch
exploratori
clinic
trial
cell
desper
measur
could
improv
live
mani
termin
ill
individu
goal
session
review
current
state
knowledg
preclin
clinic
applic
stem
cell
human
diseas
session
began
jane
onken
duke
univers
school
medicin
provid
overview
ongo
clinic
trial
standard
prepar
msc
acut
myocardi
infect
provacel
osiri
pharmaceut
inc
columbia
md
acut
gvhd
steroidresist
gvhd
prochym
osiri
pharmaceut
inc
columbia
md
updat
ongo
clinic
trial
adult
msc
crohn
diseas
prochym
msc
prepar
studi
shown
low
immunogen
thu
requir
hla
match
phase
trial
prochym
complet
steroidresist
gvhd
patient
drugrel
seriou
advers
event
studi
reduct
observ
mortal
basi
trial
phase
trial
initi
patient
acut
gvhd
shown
respons
rate
partial
complet
respons
trial
crohn
diseas
phase
openlabel
studi
subject
trial
investig
low
dose
cellskg
high
dose
cellskg
given
studi
entri
day
later
primari
outcom
measur
crohn
diseas
activ
index
cdai
clinic
respons
defin
reduct
cdai
least
day
secondari
endpoint
clinic
remiss
drop
cdai
least
improv
qualiti
life
determin
diseasespecif
questionnair
dr
onken
present
data
nine
evalu
patient
mean
decreas
cdai
individu
well
three
nine
patient
show
clinic
respons
note
three
longer
shown
respons
antitnf
therapi
studi
infusionrel
seriou
advers
event
futur
studi
design
determin
optim
dose
number
cell
frequenc
durabl
respons
suitabl
biomark
surrog
outcom
measur
examin
mucos
heal
well
longterm
safeti
donald
phinney
tulan
center
gene
therapi
school
medicin
discuss
use
cellbas
therapi
alter
lung
microenviron
use
mous
model
pulmonari
fibrosi
review
current
literatur
msc
acut
lung
injuri
phinney
lab
character
popul
immunodeplet
murin
msc
idmmsc
cultur
expand
mous
bone
marrow
day
enrich
plastic
adher
follow
immunodeplet
idmmsc
administr
immedi
bleomycin
challeng
significantli
reduc
lung
inflamm
increas
collagen
content
measur
lung
hydroxyprolin
level
day
postchalleng
use
serial
analysi
gene
express
investig
observ
signific
increas
express
receptor
antagonist
isol
idmmsc
well
increas
express
lung
bleomycininjur
mice
transfer
cell
vivo
investig
similarli
demonstr
either
system
intratrach
msc
administr
also
reduc
endotoxininduc
lung
injuri
msc
administr
associ
decreas
neutrophil
influx
well
local
tnfa
level
cxc
chemokin
express
use
serial
analysi
gene
express
sage
phinney
lab
observ
mani
immun
gene
express
idmmsc
vegf
b
pleiotrophin
macrophag
migrat
inhibitor
protein
howev
express
gene
homogen
therefor
may
subpopul
msc
could
exploit
specif
immunotherapi
daniel
weiss
univers
vermont
show
data
one
achiev
cftr
express
lung
tissu
cftr
mice
irradi
bone
marrow
transplant
level
engraft
cftrexpress
cell
despit
investig
could
measur
function
chlorid
conduct
also
report
engraft
human
cord
blood
cell
epithelium
nod
scid
mice
data
suggest
exploit
home
recruit
would
need
better
understood
improv
base
fact
msc
regulatori
properti
reduc
acut
lung
inflamm
weiss
laboratori
investig
whether
adult
mous
bone
marrowderiv
msc
provid
msc
core
facil
tulan
center
gene
therapi
could
attenu
inflamm
airway
hyperrespons
mous
model
asthma
induc
ovalbumin
administr
msc
significantli
attenu
ovalbumininduc
increas
airway
hyperrespons
well
number
eosinophil
bronchoalveolar
lavag
fluid
ovalbumin
challeng
moreov
substanti
reduct
cytokin
lung
msctreat
mice
notabl
effect
occur
syngen
allogen
msc
administr
consist
concept
msc
immunoprivileg
underscor
use
msc
current
clinic
trial
ongo
work
investig
msc
affect
dendrit
cell
activ
antigen
present
tcell
lineag
commit
tcell
effector
function
ellen
burnham
univers
colorado
health
scienc
center
spoke
role
epc
lung
diseas
idea
mani
lung
diseas
ard
pulmonari
hypertens
emphysema
asthma
bronchopulmonari
dysplasia
lung
cancer
signific
vascular
compon
pathogenesi
burnham
colleagu
previous
shown
patient
ard
epc
frequenc
flow
cytometri
coloni
format
associ
improv
surviv
howev
data
diseas
conflict
possibl
due
differ
protocol
use
immunophenotyp
cell
yoon
suggest
earli
epc
could
identifi
although
cell
express
vegf
weak
produc
nitric
oxid
poor
tube
format
contrast
lateoutgrowth
epc
lose
express
retain
much
higher
product
show
excel
angiogen
potenti
moreov
age
sex
smoke
diabet
shown
affect
epc
frequenc
may
complic
use
clinic
trial
sever
studi
shown
progenitor
cell
infus
coronari
circul
safe
one
studi
assmu
colleagu
administr
bone
marrow
progenitor
cell
associ
greater
increas
left
ventricular
function
compar
circul
progenitor
cell
dr
burnham
suggest
would
prudent
also
examin
current
drug
trial
lung
diseasesfor
exampl
ard
granulocytemacrophag
colonystimul
factor
trialto
determin
effect
epc
frequenc
blood
last
discuss
subpopul
patient
epc
therapi
may
benefici
keith
l
march
indiana
center
vascular
biolog
medicin
provid
updat
cardiac
trial
model
potenti
stem
cell
trial
lung
diseas
clinicaltrialsgov
current
list
trial
stem
cell
cardiovascular
diseas
two
clinic
trial
pulmonari
hypertens
two
clinic
investig
pulmonari
hypertens
lung
cancer
lung
diseas
major
focu
cellbas
therapi
focus
ischem
heart
diseas
acut
myocardi
infarct
despit
focu
approach
mobil
cell
type
cell
studi
vari
wide
mobil
endogen
stem
cell
growth
factor
ex
vivo
expans
defin
popul
cell
administr
whole
bone
marrow
march
laboratori
recent
describ
popul
multipot
adipos
stromal
cell
share
pericyt
mesenchym
surfac
marker
cell
resid
periendotheli
locat
contribut
endotheli
network
grown
matrigel
substrat
challeng
newer
stem
cell
popul
develop
vitro
vivo
assay
screen
multipot
success
clinic
trial
duncan
j
stewart
univers
ottawa
gave
updat
ongo
clinic
trial
epc
pulmonari
hypertens
trial
involv
popul
epc
transfect
eno
preclin
studi
use
mct
model
pah
shown
epc
deliv
day
administr
mct
prevent
pah
cell
therapi
late
week
later
also
effect
block
progress
diseas
data
led
develop
phacet
trial
doserang
studi
assess
toler
enostransfect
epc
idiopath
pah
trial
design
enrol
patient
five
dose
cohort
low
end
cell
cell
three
patient
enrol
toler
therapi
date
donald
w
fink
us
food
drug
administr
fda
close
didact
portion
session
overview
agenc
perspect
initi
earlyphas
clinic
safeti
studi
regardless
sourc
cell
adult
fetal
embryon
allogen
autolog
cellbas
therapi
regul
fda
center
biolog
evalu
research
cber
dr
fink
review
sever
key
aspect
regard
evalu
investig
new
drug
ind
applic
pertain
firstinhuman
clinic
studi
use
stem
cell
applic
must
includ
inform
cell
sourcedonor
describ
method
isol
expand
andor
differenti
stem
cell
prepar
end
investig
provid
data
reproduc
natur
cell
expansiondifferenti
assay
stabil
stem
cell
phenotyp
applic
also
describ
uniqu
characterist
stem
cellbas
cellular
product
permit
specif
analyt
test
product
assess
ident
cellular
profil
assess
immunolog
potenti
recommend
well
assay
viabil
untoward
differenti
tumorgen
due
complex
field
investig
highli
encourag
engag
agenc
preind
submiss
confer
fdacber
inform
see
http
wwwfdagov
discuss
section
led
dr
kenneth
brigham
emori
alan
fine
boston
univers
michael
matthay
univers
california
san
francisco
marc
moss
univers
colorado
ben
suratt
univers
vermont
discuss
began
question
diseas
prime
candid
stem
cell
therapi
much
excit
fact
pulmonari
commun
pois
captur
critic
safeti
toler
data
epc
trial
pah
regulatori
perspect
howev
trial
two
hurdl
clear
one
character
epc
second
transfect
procedur
trial
use
msc
acut
lung
injuri
would
requir
cell
character
basi
preclin
data
date
unclear
whether
otherwis
nongenet
engin
cell
would
effect
due
low
engraft
cell
lung
tendenc
develop
cell
therapi
acut
lung
injuri
potenti
therapi
oppos
diseas
may
requir
engraft
session
includ
present
alan
michelson
chief
laboratori
development
system
biolog
nhlbi
integr
systemslevel
approach
biolog
medicin
novel
potenti
power
mean
approach
complex
multidimension
aspect
cell
therapi
approach
lung
diseas
follow
dorothi
gail
chief
lung
biolog
diseas
branch
nhlbi
john
thoma
program
director
transfus
medicin
cellular
therapeut
nhlbi
present
nhlbi
perspect
stem
cell
cell
therapi
approach
lung
diseas
avail
resourc
nhlbi
nih
describ
includ
nih
product
assist
cellular
therapi
pact
program
http
wwwpactgroupnet
resourc
list
confer
recommend
also
includ
session
present
mike
rosenzweig
john
walsh
ceo
respect
pulmonari
fibrosi
foundat
import
stem
cell
research
particular
patient
popul
role
nonprofit
research
organ
support
novel
area
research
present
vigor
procon
discuss
held
whether
move
ahead
toward
clinic
trial
current
two
clinic
investig
stemprogenitor
cell
lung
diseas
one
lung
cancer
pulmonari
hypertens
two
trial
cell
therapi
approach
pulmonari
hypertens
list
clinicaltrialsgov
tabl
salient
point
procon
discuss
summar
tabl
overal
consensu
lung
diseas
still
present
major
challeng
probabl
time
cautious
move
ahead
care
design
trial
major
consider
mani
lung
diseas
devast
current
therapi
offer
littl
hope
patient
encourag
result
report
cell
therapi
mani
diseas
exampl
effect
therapi
medicin
fulli
understood
time
introduc
even
becam
common
medic
practic
time
consensu
far
littl
known
narrow
scope
basic
research
lung
like
open
new
avenu
therapi
reflect
session
abstract
confer
cover
broad
scope
topic
rang
basic
biolog
lung
approach
new
therapi
lung
diseas
remark
progress
made
sinc
last
confer
year
ago
area
follow
development
biolog
lung
new
system
analyz
complex
biolog
system
defin
new
subpopul
cell
lung
includ
resid
stemprogenitor
cell
defin
circul
bone
marrow
cell
contribut
repair
lung
new
mechan
cellular
differenti
among
mani
new
theme
explor
exogen
cell
bone
marrow
sourc
may
hasten
repair
lung
modul
inflammatori
immun
reaction
without
cell
engraft
long
term
differenti
pulmonari
cell
number
new
approach
cell
therapi
explor
includ
cellimpregn
scaffold
lung
repair
use
cell
transduc
express
therapeut
gene
isol
new
subpopul
cell
repair
lung
embryo
lung
circul
bone
marrow
hope
workshop
recommend
spark
new
research
provid
understand
role
stem
repar
cell
lung
biolog
provid
sound
scientif
basi
therapeut
use
adult
repar
cell
lung
diseas
follow
recommend
suggest
mani
similar
outlin
workshop
overal
confer
recommend
found
tabl
term
stem
progenitor
cell
continu
use
vari
degre
rigor
publish
studi
result
confus
misconcept
research
find
methodolog
may
problemat
given
continu
public
debat
use
stem
cell
biolog
research
furthermor
lack
consensu
among
expert
constitut
certain
stem
progenitor
popul
notabl
msc
epc
investig
urg
use
recent
isct
mesenchym
tissu
stem
cell
committe
criteria
defin
human
msc
also
possibl
may
differ
subtyp
msc
expect
criteria
updat
field
continu
develop
discuss
interact
investig
use
epc
msc
well
stem
progenitor
cell
type
encourag
help
guid
use
similar
cell
popul
compar
studi
guid
terminolog
shown
tabl
glossari
necessarili
reflect
overal
consensu
definit
term
undergo
continu
revis
overal
understand
cell
type
mechan
involv
lung
repair
continu
elucid
nonetheless
use
framework
studi
investig
gene
express
profil
normal
human
lung
tissu
lung
carcinoma
metastat
tumor
lung
express
gene
given
lung
tissu
sampl
examin
cdna
microarray
analysi
compar
normal
lung
tissu
addit
hope
identifi
particular
subset
lung
cancer
cell
enhanc
capac
prolifer
selfrenew
analog
stem
cell
recent
identifi
certain
type
leukemia
breast
cancer
brain
tumor
primari
object
establish
safeti
autolog
progenitor
cellbas
gene
therapi
heno
patient
sever
pulmonari
arteri
hypertens
refractori
convent
treatment
northern
therapeut
januari
phacet
trial
complet
enrol
firstdos
panel
three
patient
receiv
total
million
earlygrowth
epc
transfect
overexpress
human
nitric
oxid
synthetas
eno
cell
deliveri
procedur
well
toler
safeti
concern
notabl
first
three
patient
show
remark
nearli
reduct
total
peripher
vascular
resist
pvr
cours
deliveri
period
might
repres
effect
increas
releas
engin
epc
within
pulmonari
microcircul
object
goal
studi
investig
feasibl
safeti
initi
clinic
outcom
intraven
infus
autolog
endotheli
progenitor
cell
epc
patient
idiopath
pulmonari
arteri
hypertens
ipah
background
experiment
data
suggest
transplant
epc
attenu
monocrotalineinduc
pulmonari
hypertens
rat
dog
addit
clinic
studi
suggest
autolog
progenitor
cell
transplant
feasibl
safe
patient
ischem
diseas
method
conduct
prospect
random
trial
compar
effect
epc
transplant
plu
convent
therapi
convent
therapi
alon
patient
ipah
primari
endpoint
chang
sixminutewalk
distanc
use
standard
protocol
secondari
endpoint
chang
hemodynam
variabl
assess
right
heart
catheter
patient
cell
infus
group
also
signific
improv
mean
pulmonari
arteri
pressur
pulmonari
vascular
resist
cardiac
output
sever
advers
event
cell
infus
conclus
preliminari
studi
show
intraven
infus
autolog
epc
seem
feasibl
safe
might
benefici
effect
exercis
capac
pulmonari
hemodynam
patient
ipah
firm
scientif
basi
translat
approach
repair
regener
diseas
lung
use
cell
fulli
explor
promot
understand
role
cell
lung
develop
repair
remodel
number
specif
recommend
develop
follow
mani
similar
recommend
confer
rigor
techniqu
must
use
assess
potenti
situ
engraft
exogen
cell
lung
delin
popul
endogen
stem
progenitor
cell
result
obtain
routin
photomicroscopi
lung
section
detect
marker
delin
fluoresc
situ
hybrid
immunohistochem
well
techniqu
mislead
photomicroscopi
incorpor
advanc
imag
techniqu
includ
confoc
microscopi
deconvolut
microscopi
electron
microscopi
laser
captur
techniqu
applic
techniqu
includ
flow
cytometri
dna
andor
rna
analys
compar
approach
done
parallel
feasibl
function
role
endogen
stem
progenitor
cell
exogen
administ
cell
larg
unknown
differ
lung
diseas
state
furthermor
grow
number
studi
function
role
suggest
mechan
mechan
function
alter
occur
poorli
understood
addit
analysi
function
outcom
may
differ
differ
diseas
question
crucial
potenti
cell
therapeut
applic
function
outcom
includ
extent
feasibl
preclin
studi
function
outcom
tailor
specif
diseas
model
investig
function
outcom
must
sensit
high
throughput
easili
reproduc
quantit
exampl
includ
follow
express
miss
gene
gene
product
andor
measur
gene
product
function
ie
chlorid
current
follow
cftr
express
restor
pulmonari
function
highresolut
comput
tomographi
scan
histomorphometri
smallanim
pulmonari
mechan
relev
promot
greater
understand
cellular
molecular
pathophysiolog
human
disord
mani
avail
mous
model
fulli
recapitul
human
diseas
limit
extrapol
therapeut
intervent
consider
effort
direct
toward
develop
better
model
human
diseas
includ
largeanim
model
continu
develop
robust
tool
identif
character
potenti
cell
popul
high
prioriti
area
particular
mention
need
develop
tool
parallel
rodent
human
cell
diseas
model
character
cellspecif
marker
isol
prospect
character
differ
endogen
stem
progenitor
cell
popul
fda
support
care
design
initi
investigatori
trial
review
individu
basi
mani
patient
endstag
lung
diseas
alreadi
offer
particip
clinic
trial
investig
patient
endstag
lung
diseas
may
optim
popul
studi
initi
investig
provid
import
data
safeti
gener
futur
hypothes
studi
unresolv
ethic
issu
concern
unanticip
advers
outcom
earli
clinic
applic
could
impact
futur
progress
field
happen
earli
gene
therapi
trial
definit
abbrevi
epc
endotheli
progenitor
cell
fda
us
food
drug
administr
msc
mesenchym
stem
cell
condit
delet
specif
cell
popul
eg
neuroendocrin
ciliat
type
ii
cell
mediat
lung
repair
mechan
remain
incomplet
understood
endogen
stem
progenitor
cell
possibl
circul
marrowderiv
cell
like
particip
understand
role
interact
crucial
area
investig
recommend
focu
larg
exclus
util
differ
model
use
differ
proofofconcept
model
although
experiment
injuryrepair
system
eg
use
naphthalen
bleomycin
etc
necessarili
mimic
human
lung
disord
use
test
specif
hypothes
increas
focu
clinic
relev
diseas
model
increas
use
investig
lung
regener
model
suggest
model
includ
postpneumonectomi
regener
septal
prolifer
retino
acid
treatment
nutrit
neonat
depriv
etc
investig
differ
plasticitydedifferenti
model
includ
labelretain
tissu
stem
cell
model
endogen
stem
progenitor
cell
investig
basic
develop
repair
mechan
includ
follow
mechan
normal
lineag
specif
epitheli
interstiti
endotheli
cell
mechan
epithelialendothelialinterstiti
interact
cellmatrix
interact
identif
stemprogenitor
cell
nich
form
maintain
impact
lung
remodel
nich
impact
age
diseas
immun
system
regen
capac
micrenvironment
nich
endogen
stem
progenitor
cell
resid
critic
affect
behavior
sophist
tool
mimic
ex
vivo
relev
microenviron
studi
endogen
stem
progenitor
cell
requir
structur
engraft
believ
rarer
occurr
first
postul
nonetheless
structur
engraft
epitheli
interstiti
pulmonari
vascular
cell
occur
mechan
cell
recruit
lung
andor
induc
undergo
convers
function
lung
cell
remain
poorli
understood
furthermor
mani
variabl
chronic
lung
diseas
model
age
rout
cell
administr
forth
remain
less
well
explor
develop
appropri
vivo
model
system
includ
transgen
mice
use
gene
transfer
techniqu
condit
target
overexpress
candid
recruit
mediat
demonstr
function
relev
identifi
potenti
recruit
mechan
explor
factor
might
influenc
recruit
phenotyp
convers
follow
diseas
model
ie
acut
vs
chronic
lung
injuri
b
age
cell
recipi
lung
c
rout
dose
frequenc
cell
administr
time
administr
relat
lung
injuri
e
yet
unidentifi
cell
popul
addit
vivo
studi
delin
develop
robust
vitro
model
system
crucial
understand
role
endogen
stem
progenitor
cell
circul
exogen
administ
cell
lung
biolog
diseas
develop
method
vitro
expans
lung
progenitor
stem
cell
expans
improv
method
test
cell
therapi
includ
limit
follow
cultur
without
feeder
cell
cultur
without
growth
factorsserumretinoid
cultur
use
differ
substrata
combin
cultur
mesenchym
graft
permiss
tissu
kidney
capsul
expans
airliquid
interfac
cultur
studi
use
tracheal
heterotop
transplant
modelseith
denud
inocul
cell
differ
sourc
repopul
endogen
cell
parallel
improv
vitro
cultur
method
develop
novel
approach
use
artif
matric
threedimension
scaffold
ex
vivo
subsequ
vivo
lung
regener
desir
effect
mechan
forc
lung
develop
repair
incorpor
vitro
studi
develop
method
cultur
stem
progenitor
cell
artifici
cadaver
matric
threedimension
scaffold
vitro
develop
method
vivo
assess
cell
grown
artifici
matric
threedimension
scaffold
assess
mechan
forc
effect
develop
lung
tissu
stem
progenitor
cell
popul
pro
con
whether
establish
core
center
train
cell
cultur
gener
provis
specif
cell
type
function
outcom
assess
histolog
assess
methodolog
techniqu
discuss
follow
recommend
made
highli
desir
goal
inform
educ
stem
cell
commun
potenti
role
stem
repar
cell
lung
biolog
diseas
convers
lung
commun
need
educ
stem
repar
cell
biolog
lead
fruit
interact
collabor
importantli
result
less
overlap
duplic
research
effort
educ
program
nation
meet
stem
cell
train
cours
didact
practic
compon
differ
disciplin
grow
impetu
move
toward
initi
safeti
efficaci
clinic
investig
base
part
initi
result
phacet
trial
univers
toronto
part
recent
demonstr
safeti
efficaci
phase
trial
use
msc
crohn
diseas
gvhd
acknowledg
particip
mechan
shortand
longterm
effect
cellbas
therapi
lung
diseas
remain
unknown
furthermor
remain
concern
whether
cell
epc
msc
may
contribut
develop
lung
cancer
may
increas
fibrot
reaction
nonetheless
vigor
discuss
follow
recommend
clinic
translat
studi
made
see
also
tabl
proceed
design
implement
initi
exploratori
safeti
investig
appropri
ethic
issu
consid
clinic
translat
investig
includ
consider
mechan
cell
action
limit
simpl
outcom
measur
care
consider
given
sampl
collect
ie
blood
bronchoalveolar
lavag
fluid
biopsi
etc
alreadi
exist
clinic
trial
wherein
analys
sampl
might
provid
insight
potenti
role
mechan
lung
remodel
adult
repar
cell
central
coordin
center
consid
take
advantag
appropri
distribut
clinic
sampl
ensur
maxim
use
nih
fda
relev
agenc
work
close
togeth
defin
paramet
adequ
cell
product
character
well
preclin
proofofconcept
toxicolog
test
support
design
supervis
phase
clinic
trial
continu
accumul
data
anim
model
clinic
trial
suggest
cellbas
therapi
may
potenti
therapeut
strategi
lung
repair
remodel
injuri
parallel
understand
role
endogen
lung
progenitor
cell
provid
insight
mechan
lung
develop
repair
injuri
may
also
provid
novel
therapeut
strategi
hope
workshop
recommend
spark
new
research
provid
understand
mechan
repair
lung
injuri
provid
sound
scientif
basi
therapeut
use
stem
cell
therapi
lung
diseas
list
confer
particip
execut
summari
speaker
present
poster
abstract
includ
onlin
supplement
